Ms. Yang Ling 楊凌
- Managing Director, The Carlyle Group
Ling Yang is a Managing Director at The Carlyle Group. She is co-head of Carlyle Asia Healthcare and is primarily responsible for Carlyle’s healthcare investment and portfolio activities in China. Ms. Yang began her career at Carlyle focusing on healthcare for the U.S. Buyout group and joined Carlyle Asia in 2011. Since joining Carlyle Asia, Ms. Yang has led investments into leading healthcare companies in China including Hutchmed, Adicon Clinical Laboratories, Ambiopharm, Microport Scientific Corporation, Meinian Onehealth, and Shenzhen Salubris Pharmaceuticals. She chairs the board of Adicon Clinical Laboratories and is a member of the boards of Ambiopharm and Shenzhen Salubris.
楊凌女士現任職於凱雷投資集團，擔任董事總經理職位，是凱雷亞洲醫療健康業務的聯席主管，主要負責凱雷在大中華區醫療行業的投資業務。楊女士在凱雷投資集團美國併購組開始職業生涯，專注於醫療行業，並於2011年加入凱雷亞洲。自加入凱雷亞洲以來，楊凌女士已領導了多個對中國一些最具活力的醫療投資項目，其中包括和黃醫藥、艾迪康醫學檢驗中心、昂博生物、微創醫療科學，美年大健康和深圳信立泰藥業。她目前擔任艾迪康醫學檢驗中心的董事長，以及深圳信立泰藥業與昂博生物的董事會成員。